Nautic Partners, a private equity firm, has acquired Mikart, a contract development and manufacturing company based in Atlanta, GA, specializing in the development, manufacture and packaging of solid dose and non-sterile liquid pharmaceuticals. Michael Kallelis has been appointed chief executive officer of Mikart.
 
For over 40 years, Mikart has provided comprehensive commercialization services including formulation development, clinical trial supplies, regulatory filing support, analytical services, clinical manufacturing, commercial manufacturing, and packaging. Ongoing investments in the business include serialization-compliant packaging lines.
 
Michael Kallelis has more than 30 years of experience in public and private life sciences companies, where he has successfully implemented commercial and operational growth strategies. Most recently, Mike was vice president of business development, at KMC Systems.
 
He also served as chief operating officer and co-founder of Boston BioSystems, an API contract manufacturing company, making GMP grade, synthetic oligonucleotides. Boston BioSystems was acquired by Avecia Ltd., a UK based former division of AstraZeneca.
 
Mike was also president and chief operating officer at Exiqon, a gene expression analysis company, which he helped take public in 2007. Mike has held senior roles at GE Life Sciences, Millipore and Sepracor, where he managed technologies directed at diagnostics, genomics, proteomics, bioprocessing and drug development.